<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01713166</url>
  </required_header>
  <id_info>
    <org_study_id>YSJeon_crystalloid vs colloid</org_study_id>
    <nct_id>NCT01713166</nct_id>
  </id_info>
  <brief_title>Effects of Colloid and Crystalloid on the Microcirculatory Alterations During Off-pump Coronary Artery Bypass Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of crystalloid and colloid, which are
      used for pump priming solution, on the microcirculatory alterations during cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery slope</measure>
    <time_frame>until 2 days after surgery</time_frame>
    <description>Recovery slope is a marker of microcirculation. The tissue oxygen saturation (StO2) using InspectraTM StO2 (Hutchinson Technology Inc.,USA) will be recorded continuously. The InspectraTM StO2 probe will be placed on the skin of the thenar eminence and the blood pressure cuff will be wrapped around the arm. After performing vascular occlusion test, the recovery slope will be calculated by the software.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>syndecan-1</measure>
    <time_frame>until 2 days after surgery</time_frame>
    <description>marker of glycocalyx degradation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lactate</measure>
    <time_frame>until 2 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>StO2 (tissue oxygen saturation)</measure>
    <time_frame>until 2 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine</measure>
    <time_frame>until 2 days after surgery</time_frame>
    <description>Interleukin (IL)-1b, IL-6, IL-8, IL-10, TNF-a</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Plasmalyte solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plasmalyte solution infusion to meet the fluid requirements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hextend</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>plasmalyte solution</intervention_name>
    <description>plasmalyte solution</description>
    <arm_group_label>Plasmalyte solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hextend</intervention_name>
    <description>Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.</description>
    <arm_group_label>Hextend</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Off-pump Coronary Artery Bypass Surgery

        Exclusion Criteria:

          -  Infection

          -  Postoperative use of steroid

          -  Liver cirrhosis, Child-Pugh C

          -  Renal disease on hemodialysis

          -  Patients who cannot receive vascular occlusion test (severe peripheral vascular
             disease, arteriovenous fistula, burn)

          -  EF &lt; 40% on the preoperative echocardiography

          -  Preoperative use of vasopressors or inotropic agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2012</study_first_submitted>
  <study_first_submitted_qc>October 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yunseok Jeon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

